Tumor necrosis factor α induces γ-glutamyltransferase expression via nuclear factor-κB in cooperation with Sp1

Reuter, Simone; Schnekenburger, Michaël; Cristofanon, Silvia; Buck, Isabelle; Teiten, Marie Hélène; Daubeuf, Sandrine; Eifes, Serge; Dicato, Mario; Aggarwal, Bharat B.; Visvikis, Athanase; Diederich, Marc

doi:10.1016/j.bcp.2008.09.041

Cited by 42 publications

(33 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, it remains to be unexplained that the use of thalidomide was not associated with significant changes in sTNFRII levels. In spite of the improvement of liver enzymes in our study, and that GGT levels seems to be a surrogate marker of TNF-α levels and inflammatory state (51). In contrast, Milazzo detected a reduced TNF-α production by stimulated PBMC in vitro (22).…”

Section: Discussioncontrasting

confidence: 83%

Thalidomide with peginterferon alfa-2b and ribavirin in the treatment of non-responders genotype 1 chronic hepatitis C patients: proof of concept

Pardo-Yules

Gallego‐Durán²,

Eslam

et al. 2011

Rev. esp. enferm. dig.

View full text Add to dashboard Cite

Background: fewer than half of patients infected with hepatitis C virus (HCV) achieve sustained viral clearance after peginterferon alfa/ribavirin (Peg-IFN/RBV) therapy.Aims: thalidomide posses anti-inflammatory and immunomodulatory properties through inhibition of tumor necrosis factor and costimulatory effect on human CD8+ T cells.Methods: we started a prospective, open label trial of retreatment of very-difficult-to-treat genotype 1 chronic hepatitis C patients (CHC) patients, who had failed to respond to the (Peg-IFN/RBV), with a triple therapy consisting in these same antivirals plus thalidomide 200 mg/day (the TRITAL study).Results: none of the eleven patients fulfilling the inclusion criteria and included in the trial reached complete early virological response or sustained virological response. Viral load decline after 12 weeks of triple therapy thalidomide-based retreatment did not differ from viral dynamics during the first course. The triple therapy was well tolerated and only one patient developed mild bilateral neuropathy.Conclusions: thalidomide addition to standard therapy is tolerated and did not increase the SVR rate in very-difficult-to-treat genotype 1 CHC patients. Different schedules are warranted to improve attempting retreatment of non responder CHC patients.

show abstract

Section: Discussioncontrasting

confidence: 83%

Thalidomide with peginterferon alfa-2b and ribavirin in the treatment of non-responders genotype 1 chronic hepatitis C patients: proof of concept

Pardo-Yules

Gallego‐Durán²,

Eslam

et al. 2011

Rev. esp. enferm. dig.

View full text Add to dashboard Cite

show abstract

“…The first step in glutathione degradation involves addition of amino acids to form γ-glutamyl amino acids [24], as catalyzed by γ-glutamyltransferase (GGT). The pro-inflammatory cytokine TNF-α has been shown increase GGT expression [25], evidence that suggests γ-glutamyl amino acids as markers of inflammation in subjects with elevated lean mass. In contrast, results obtained for cortisone and stearoyl sphingomyelin are suggestive of decreased inflammation in subjects with elevated percent lean mass.…”

Section: A C C E P T E Dmentioning

confidence: 99%

Serum Predictors of Percent Lean Mass in Young Adults

Lustgarten

Price

Phillips

et al. 2016

Journal of Strength and Conditioning Research

View full text Add to dashboard Cite

Lustgarten, MS, Price, LL, Phillips, EM, Kirn, DR, Mills, J, and Fielding, RA. Serum predictors of percent lean mass in young adults. J Strength Cond Res 30(8): 2194-2201, 2016-Elevated lean (skeletal muscle) mass is associated with increased muscle strength and anaerobic exercise performance, whereas low levels of lean mass are associated with insulin resistance and sarcopenia. Therefore, studies aimed at obtaining an improved understanding of mechanisms related to the quantity of lean mass are of interest. Percent lean mass (total lean mass/body weight × 100) in 77 young subjects (18-35 years) was measured with dual-energy x-ray absorptiometry. Twenty analytes and 296 metabolites were evaluated with the use of the standard chemistry screen and mass spectrometry-based metabolomic profiling, respectively. Sex-adjusted multivariable linear regression was used to determine serum analytes and metabolites significantly (p ≤ 0.05 and q ≤ 0.30) associated with the percent lean mass. Two enzymes (alkaline phosphatase and serum glutamate oxaloacetate aminotransferase) and 29 metabolites were found to be significantly associated with the percent lean mass, including metabolites related to microbial metabolism, uremia, inflammation, oxidative stress, branched-chain amino acid metabolism, insulin sensitivity, glycerolipid metabolism, and xenobiotics. Use of sex-adjusted stepwise regression to obtain a final covariate predictor model identified the combination of 5 analytes and metabolites as overall predictors of the percent lean mass (model R = 82.5%). Collectively, these data suggest that a complex interplay of various metabolic processes underlies the maintenance of lean mass in young healthy adults.

show abstract

“…Recently, we provided evidence that nature provides excellent inhibitors of NF-jB: we showed that curcumin [21][22][23]; b-lapachone and emodin, sanguinarine, and capsaicin [24]; kawains [25]; naphtopyrones [26]; cardenolides [27,28]; heteronemin [29]; polyketide derivatives [30]; chalcones [31,32]; and neem leaf extract [33] efficiently inhibit NF-jB cell signaling pathways. Recent reports demonstrate that this is a very active field of research worldwide [6,22,[34][35][36][37][38][39].…”

Section: Nuclear Factor Kappa B Cell Signaling Pathwaysmentioning

confidence: 97%

Anti-Inflammatory and Anticancer Drugs from Nature

Orlikova

Legrand

Panning

et al. 2013

Cancer Treatment and Research

Self Cite

View full text Add to dashboard Cite

Over the centuries, plant extracts have been used to treat various diseases. Until now, natural products have played an important role in anticancer therapy as there are more than 500 compounds from terrestrial and marine plants or microorganisms, which have antioxidant, antiproliferative, or antiangiogenic properties and are therefore able to reduce tumor growth. The recent discovery of new natural products has been accelerated by novel technologies (high throughput screening of natural products in plants, animals, marine organisms, and microorganisms). Vincristine, irinotecan, etoposide, and paclitaxel are examples of compounds derived from plants that are used in cancer treatment. Similarly, actinomycin D, mitomycin C, bleomycin, doxorubicin, and L-asparaginase are drugs derived from microorganisms. In this review, we describe the molecular mechanisms of natural compounds with anti-inflammatory and anticancer activities.

show abstract

Tumor necrosis factor α induces γ-glutamyltransferase expression via nuclear factor-κB in cooperation with Sp1

Cited by 42 publications

References 55 publications

Thalidomide with peginterferon alfa-2b and ribavirin in the treatment of non-responders genotype 1 chronic hepatitis C patients: proof of concept

Thalidomide with peginterferon alfa-2b and ribavirin in the treatment of non-responders genotype 1 chronic hepatitis C patients: proof of concept

Serum Predictors of Percent Lean Mass in Young Adults

Anti-Inflammatory and Anticancer Drugs from Nature

Contact Info

Product

Resources

About